Rheumatoid Arthritis. Other rheumatoid arthritis
Conditions
Interventions
Sponsors
Mashhad University of Medical Sciences
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patient with Rheumatoid Arthritis diagnosis (according to ACR/EULAR) DAS28 > 2.5 (after 3 months of 7.5 mg methotrexate and 5 mg prednisolone) Satisfaction for participation in the research project
Exclusion criteria
Exclusion criteria: Uncontrolled and severe adverse event Unwilling to continue the research project
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Assessment of disease activity. Timepoint: Baseline and after 12 weeks. Method of measurement: Disease Activity Score (DAS28).;Measure change in rheumatoid arthritis symptoms. Timepoint: Baseline and after 12 weeks. Method of measurement: ACR (American College of Rheumatology) score. | — |
Secondary
| Measure | Time frame |
|---|---|
| Quality of life. Timepoint: Baseline and after 12 weeks. Method of measurement: Health Assessment Questionnaire-Disability Index (HAQ-DI).;Assessment of Disease Activity. Timepoint: Baseline and after 12 weeks. Method of measurement: US-7 score (by ultrasonography of seven preselected joints).;Erythrocyte Sedimentation Rate (ESR). Timepoint: Baseline and after 12 weeks. Method of measurement: Blood test.;C-reactive protein. Timepoint: Baseline and after 12 weeks. Method of measurement: Blood test.;Interleukin 6 (IL6). Timepoint: Baseline and after 12 weeks. Method of measurement: Blood test. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMaryam Emadzadeh
Mashhad University of Medical Sciences
Outcome results
None listed